Absci (ABSI) investor relations material

Strategic direction and technology advancements

• Transitioned from protein-protein interaction research to a generative AI-native platform integrating automated wet-lab and advanced AI for rapid, capital-efficient drug discovery, targeting hard-to-drug proteins like GPCRs and ion channels.

• Developed proprietary AI platforms (Origin-1, Origin-2, AbsciDiff, AbsciGen, AbsciBind) enabling zero-shot epitope targeting, de novo antibody design, and successful drugging of previously intractable targets.

• Demonstrated ability to design antibodies with desired properties for novel and challenging targets, validated by cryo-EM and ex vivo studies.

• Leveraged AI to reduce clinical entry costs to $10–15 million versus traditional $50+ million, with drug discovery cycles as short as 24 months.

• Established partnerships with major pharma companies and expanded internal pipeline, generating large IP portfolios.

Clinical pipeline and key assets

• ABS-201 leads a differentiated pipeline, targeting androgenetic alopecia (AGA) and endometriosis, with additional preclinical programs in metabolism and immunology.

• ABS-201 is in Phase 1/2a for AGA, with interim proof-of-concept readout expected in 2H 2026 and topline data in early 2027.

• Endometriosis program for ABS-201 expects Phase 2 initiation in Q4 2026, addressing a large unmet need with a novel, non-hormonal mechanism.

• Early-stage assets complementing the prolactin receptor pathway are in development.

• Clinical studies progressing as planned, with imminent release of SAD safety, tolerability, and PK data, and MAD portion of the AGA study underway.

Scientific findings and preclinical data

• ABS-201 demonstrates superior efficacy to minoxidil in preclinical hair regrowth models, with durable effects in primate studies and long-term regenerative outcomes.

• Ex vivo human scalp studies confirm mechanism of action, prolonging anagen phase, protecting stem cells, and stimulating key growth factors in both male and female samples.

• ABS-201 increases key growth factors (FGF 7, IGF 1) and Collagen 17A1, supporting durable hair regrowth.

• Prolactin receptor blockade reduces apoptosis of K15 stem cells and supports follicle health.

• In endometriosis models, ABS-201 reduces lesion formation and pain, with a differentiated safety and efficacy profile compared to current therapies.